UPTAKE OF BIOSIMILAR INFLIXIMAB: BUDGET SAVINGS OR MARKET EXPANSION ACROSS COUNTRIES?

被引：0
|
作者：
Kim, Y. [1 ]
Kwon, H. Y. [2 ]
Godman, B. [3 ]
Moorkens, E. [4 ]
Simoens, S. [4 ]
Bae, S. [1 ]
机构：
[1] Ewha Womans Univ, Coll Pharm, Seoul, South Korea
[2] Mokwon Univ, Seoul, South Korea
[3] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland
[4] Katholieke Univ Leuven, Leuven, Belgium
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PBI45
引用
收藏
页码：S425 / S425
页数：1
相关论文
共 50 条
  • [21] Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
    Brodszky, Valentin
    Baji, Petra
    Balogh, Orsolya
    Pentek, Marta
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2014, 15 : S65 - S71
  • [22] EXPLORING BIOSIMILAR MARKET ACCESS CONSIDERATIONS ACROSS THE EU
    Walker, L.
    Hewitt, C.
    Craddy, P.
    Foxon, G.
    VALUE IN HEALTH, 2018, 21 : S204 - S204
  • [23] Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
    Moorkens, Evelien
    Barcina Lacosta, Teresa
    Vulto, Arnold G.
    Schulz, Martin
    Gradl, Gabriele
    Enners, Salka
    Selke, Gisbert
    Huys, Isabelle
    Simoens, Steven
    PHARMACEUTICALS, 2020, 13 (10) : 1 - 20
  • [24] Different safety reporting profiles of infliximab biosimilar from originator: Comparison among countries
    Sai, Kimie
    Aoki, Yoshiko
    Saito, Yoshiro
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 19 - 19
  • [25] Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database
    Kim, Jiyoun
    Ha, Dongmun
    Song, Inmyung
    Park, Haesun
    Lee, Sang-Won
    Lee, Eui-Kyung
    Shin, Ju-Young
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (06) : 1227 - 1236
  • [26] Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022
    Roberts, Eric T.
    Li, Jing
    Bansback, Nick
    Tseng, Chien-Wen
    Shiboski, Steve
    Schmajuk, Gabriela
    Yazdany, Jinoos
    ARTHRITIS & RHEUMATOLOGY, 2024,
  • [27] A ratio or budget benchmark for comparing affordability across countries?
    Kristof Heylen
    Marietta Haffner
    Journal of Housing and the Built Environment, 2013, 28 : 547 - 565
  • [28] A ratio or budget benchmark for comparing affordability across countries?
    Heylen, Kristof
    Haffner, Marietta
    JOURNAL OF HOUSING AND THE BUILT ENVIRONMENT, 2013, 28 (03) : 547 - 565
  • [29] Filgrastim and infliximab biosimilar uptake in Medicare Advantage compared with Traditional Medicare, 2016-2019
    Liu, Angela
    Xuan, Andrew
    Socal, Mariana
    Anderson, Gerard
    Anderson, Kelly E.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (01): : 15 - 21
  • [30] TECHNOLOGY, KEY TO MARKET EXPANSION FOR DEVELOPING COUNTRIES
    ROMAN, D
    INDUSTRIAL MARKETING MANAGEMENT, 1974, 3 (03) : 167 - 176
12345